



(86) Date de dépôt PCT/PCT Filing Date: 2009/03/10
(87) Date publication PCT/PCT Publication Date: 2009/09/17
(45) Date de délivrance/Issue Date: 2019/08/06
(85) Entrée phase nationale/National Entry: 2010/09/09
(86) N° demande PCT/PCT Application No.: EP 2009/052797
(87) N° publication PCT/PCT Publication No.: 2009/112496
(30) Priorités/Priorities: 2008/03/10 (EP08300138.8);
2008/03/10 (US61/035,146)


(51) Cl.Int./Int.Cl. *C12N 5/077* (2010.01),
C12N 5/073 (2010.01), *C12N 5/0735* (2010.01),
C12Q 1/04 (2006.01), *G01N 33/569* (2006.01)

(72) Inventeurs/Inventors:
MENASCHE, PHILIPPE, FR;
PUCEAT, MICHEL, FR;
LARGHERO, JEROME, FR;
...

(73) Propriétaires/Owners:
ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, FR;
INSTITUT NATIONAL DE LA SANTE ET DE LA
RECHERCHE MEDICALE (INSERM), FR;
UNIVERSITE PARIS DESCARTES, FR; ...

(54) Titre : PROCEDE DE GENERATION DE CELLULES PROGENITRICES CARDIOVASCULAIRES PRIMATES POUR
USAGE CLINIQUE A PARTIR DE CELLULES EMBRYONNAIRES SOUCHES PRIMATES OU DE CELLULES A
L'ETAT EMBRYONNAIRE, ET LEURS APPLICATIONS

(54) Title: METHOD FOR GENERATING PRIMATE CARDIOVASCULAR PROGENITOR CELLS FOR CLINICAL USE
FROM PRIMATE EMBRYONIC STEM CELLS OR EMBRYONIC-LIKE STATE CELLS, AND THEIR APPLICATIONS



(57) **Abrégé/Abstract:**

The present invention is directed to a method for the in vitro preparation of cardiovascular progenitors cells from mammalian embryonic stem cells (ES cells) or mammalian embryonic-like state cells, preferably from primate, wherein said method comprises

(72) **Inventeurs(suite)/Inventors(continued):** BLIN, GUILLAUME, FR; NURY, DAVID, FR; STEFANOVIC, SONIA, FR

(73) **Propriétaires(suite)/Owners(continued):**UNIVERSITE PARIS DIDEROT PARIS 7, FR

(74) **Agent:** FASKEN MARTINEAU DUMOULIN LLP

(57) **Abrégé(suite)/Abstract(continued):**

the use of the CD15(SSEA1) marker as a positive cardiovascular progenitors differentiation marker. The present invention also claimed the use of a receptor tyrosine kinase inhibitor, particularly the SU5402 or SU11248 in association with the BMP2 for improving the efficiency of the desired differentiation. The present invention is also directed to the use of platelet lysate as foetal animal serum substitute in a culture medium intended to the proliferation or propagation of primate ES cells maintaining their pluripotency feature. Derived compositions or kits in relation with the claimed methods or product obtainable by the claimed methods form also part of the present invention.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 September 2009 (17.09.2009)



(10) International Publication Number
WO 2009/112496 A1

(51) International Patent Classification:
C12N 5/06 (2006.01)

(21) International Application Number:
PCT/EP2009/052797

(22) International Filing Date:
10 March 2009 (10.03.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/035,146 10 March 2008 (10.03.2008) US
08300138.8 10 March 2008 (10.03.2008) EP

(71) Applicants (for all designated States except US): **ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS** [FR/FR]; 3, avenue Victoria, F-75004 Paris (FR). **INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)** [FR/FR]; 101, rue de Tolbiac, F-75013 Paris (FR). **UNIVERSITE PARIS DESCARTES** [FR/FR]; 12, rue de l'Ecole de Médecine, F-75006 Paris (FR). **UNIVERSITE PARIS DIDEROT PARIS 7** [FR/FR]; 5, rue Thomas Mann, F-75013 Paris (FR). **UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES** [FR/FR]; Place Eugène Bataillon, F-34000 Montpellier (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MENASCHE, Philippe** [FR/FR]; 95, rue de Rennes, F-75006 Paris

(FR). **PUCEAT, Michel** [FR/FR]; 29, rue de la Bigotte, F-91750 Champcueil (FR). **LARGHERO, Jérôme** [FR/FR]; 33-35 rue Anna Jacquin, F-92100 Boulogne-billancourt (FR). **BLIN, Guillaume** [FR/FR]; 25, rue du Petit Mennecy, F-91540 Mennecy (FR). **NURY, David** [FR/FR]; 5E 28, rue Félicien Rops, F-91100 Corbeil (FR). **STEFANOVIC, Sonia** [FR/FR]; 9bis, rue des mésanges, F-91210 Draveil (FR).

(74) Agent: **WARCOIN, AHNER, TEXIER, LE FORESTIER, CALLON DE LAMARCK, COLLIN, TETAZ-Cabinet Regimbeau**; 20, rue de Chazelles, F-75847 Paris Cedex 17 (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE,

[Continued on next page]

(54) Title: METHOD FOR GENERATING PRIMATE CARDIOVASCULAR PROGENITOR CELLS FOR CLINICAL USE FROM PRIMATE EMBRYONIC STEM CELLS OR EMBRYONIC-LIKE STATE CELLS, AND THEIR APPLICATIONS




FIGURE 10A

(57) Abstract: The present invention is directed to a method for the in vitro preparation of cardiovascular progenitors cells from mammalian embryonic stem cells (ES cells) or mammalian embryonic-like state cells, preferably from primate, wherein said method comprises the use of the CD15 (SSEA1) marker as a positive cardiovascular progenitors differentiation marker. The present invention also claimed the use of a receptor tyrosine kinase inhibitor, particularly the SU5402 or SU11248 in association with the BMP2 for improving the efficiency of the desired differentiation. The present invention is also directed to the use of platelet lysate as foetal animal serum substitute in a culture medium intended to the proliferation or propagation of primate ES cells maintaining their pluripotency feature. Derived compositions or kits in relation with the claimed methods or product obtainable by the claimed methods form also part of the present invention.

WO 2009/112496 A1

WO 2009/112496 A1



ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR),
OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*

Method for generating primate cardiovascular progenitor cells for clinical use from primate embryonic stem cells or embryonic-like state cells, and their applications

5 The present invention is directed to a method for the in vitro preparation of cardiovascular progenitors cells from mammalian embryonic stem cells (ES cells) or mammalian embryonic-like state cells, preferably from primate, wherein said method comprises the use of the CD15 (SSEAI) marker as a positive cardiovascular progenitors differentiation marker. The present invention also claimed the use of a receptor tyrosine
10 kinase inhibitor, particularly the SU5402 or SU11248 in association with the BMP2 for improving the efficiency of the desired differentiation. The present invention is also directed to the use of platelet lysate as foetal animal serum substitute in a culture medium intended to the proliferation or propagation of primate ES cells maintaining their pluripotency feature. Derived compositions or kits in relation with the claimed
15 methods or product obtainable by the claimed methods form also part of the present invention.

 Heart failure is becoming a predominant disease and a leading cause of death in most of developed countries. Regardless of the origin of myocardial failure (i.e,
20 ischemic or genetic), the clinical symptoms result mainly from the death of cardiomyocytes replaced by a fibrotic and non contractile tissue. Pharmacological approaches to cure or relieve heart failure have been facing limitations. Because of a limited regeneration capability of the heart [1] and a shortage in donors for heart transplantation, an external source of cells has been envisioned as a therapeutic solution
25 to bring a gain in function to diseased myocardium. For the last few years, hematopoietic stem cells had raised many hopes as a potential autologous cell source to repair diseased myocardium. However, the enthusiasm generated by the early non-controlled phase I studies has been dampened by the more recent recognition that out of four randomised controlled trials entailing intracoronary infusions of bone marrow-
30 derived cells shortly after myocardial infarction, three failed to meet their primary end point, i.e., an improvement in left ventricular ejection fraction [2-5]. Combined with basic studies disproving the cardiogenic potential of these cells [6-7], the outcome of

these trials demonstrates that these cells do not really regenerate the diseased myocardium and it is unlikely that their paracrine effects may be sufficient for restoring function of extensively scarred myocardium [8]. The same limitations apply to skeletal myoblasts [9]. Thus, these findings call for another stem cell source to achieve myocardial regeneration. Among various other cell types, embryonic stem (ES) cells [10-12] or ES cell-derived cardiomyocytes [13-14] have turned out to be the most promising for replacing scar fibrosis by new contractile elements. However, the number of cells required to regenerate a post-infarcted human myocardium (i.e., several hundreds of million) is too high to be reasonably achieved by in vitro engineering of ES cell-derived cardiomyocytes. For the last few years, we and others have shown that proliferative mouse ES cells engrafted in a diseased myocardium further differentiate into functional cardiomyocytes following in-vitro commitment using the cardiogenic morphogen BMP2 [10-12]. Cardiac-specified cells then complete their differentiation in response to the local cues present in the scar and do not generate any kind of tumors.

Primate Embryonic stem (ES) cells feature the capability to self-renew and to differentiate in any cell lineage of the three embryonic layers namely the ectoderm, endoderm and mesoderm [35]. However, spontaneous differentiation of ES cells toward a specific cell lineage is poorly efficient, specifically for primate ES cells. Human ES cells do not share with mouse ES cells the same molecular mechanisms of self-renewal or capabilities of spontaneous differentiation [15]. For the last decade, laboratories have developed protocols to direct mouse and human ES (HES) cells toward their favourite cell type. These protocols are mandatory to: (i) better investigate and thus comprehend the genetic and epigenetic mechanisms underlying ES cell differentiation, (ii) use ES cells-derived differentiated cells as a toxicology model (iii) perform HTS (High Throughput Screening) aiming at discovering new cardiogenic molecules, markers of cardiac genetic diseases or new therapeutic drugs [36-37] (iv) design protocols of cell therapy of heart failure [38].

There is a clear need, therefore, to provide clinical grade cells which can subsequently differentiate into cardiomyocytes in situ following their transplantation in infarcted myocardium without any sign of hyperproliferation, by a method able to

specifically differentiate *in vitro* a high number of primate ES cells or embryonic-like state cells toward a cardiovascular lineage.

In this context, it would be worthwhile to have further at one's disposal a simple and reproducible protocol to commit primate ES cells or embryonic-like state cells
5 toward a cardiovascular lineage allowing to sort out the population of early cardiovascular progenitors which retain the capability to proliferate and repopulate the postinfarction scar.

This is the object of the present invention.

Herein, the inventors bring the proof of concept that primate ES cells such as
10 Human ES cells or embryonic-like state cells, can also be directed toward a cardiogenic and vascular fate using the morphogen BMP2 in association with a receptor tyrosine kinase inhibitor and to selectively collect these cardiovascular progenitors thus obtained by using the positive CD15 (SSEA1) biomarker. Furthermore, the cells do differentiate into cardiomyocytes following engraftment into the myocardial scar without any sign of
15 hyperproliferation. These data open the path for the use of early cardiovascular progenitors, which retain the capability to proliferate and repopulate the postinfarction scar.

Thus, the present invention relates to methods for obtaining substantially pure
20 populations of primate cardiovascular progenitors as well as compositions such as therapeutical composition, containing these cell populations and method of using these cell populations.

In a first aspect, the invention is directed to an *in vitro* method for the preparation of cardiovascular progenitors cells from mammalian ES cells or from
25 mammalian embryonic-like state cells, preferably for the preparation of a substantially purified population of cardiovascular progenitors, wherein said method comprises the following step of:

- a) culturing of mammalian ES cells or embryonic-like state cells in a medium containing suitable agents allowing their proliferation and maintaining their
30 pluripotency;
- b) differentiating the mammalian pluripotent ES cells or embryonic-like state cells obtained in step a) toward cardiovascular progenitors cells by suspending said

pluripotent ES cells or embryonic-like state cells in a medium containing BMP2 (Bone Morphogenetic Protein 2); and

c) selecting and collecting the differentiated mammalian ES cells or mammalian embryonic-like state cells obtained in step b) which display the CD15 marker at their
5 membrane surface, the mammalian ES cells or embryonic-like state cells displaying said CD15 marker being selecting and collecting as cardiovascular progenitors cells.

In a preferred embodiment, said embryonic-like state cells are induced pluripotent stem cells, commonly abbreviated as iPS cells, preferably from adult somatic cells, particularly from adult fibroblast.

10 In a more preferred embodiment, said iPS cells are obtained using human dermal fibroblasts infected by lentivirus harbouring the cDNAs encoding Oct4, Sox2, Lin 28, Klf4 and Nanog, preferably under ES cells culture conditions [49].

By “pluripotency”, it is intended to designate herein pluripotent ES cells-derived cells that are the descendants of totipotent embryonic stem cells and can differentiate
15 into cells derived from any of the three germ layers ectoderm, endoderm and mesoderm.

By iPS cells, it is intended to designate pluripotent stem cell artificially derived from a non-pluripotent cell, typically an adult somatic cell, by inducing expression of certain genes.

The preparation of iPS cells from mammalian cells, particularly from mouse
20 cells or from human cells is well known from the skilled person. [46-49].

In a preferred embodiment, the invention is directed to an *in vitro* method according to the present invention wherein said mammalian cells are primate, mouse or rat cells, preferably primate cells and more preferably human cells.

Primate embryonic stem cells can be isolated from blastocysts of members of the
25 primate species (see for example U.S. Pat. No. 5,843,780; Thomson et al., Proc. Natl. Acad. Sci. USA 92:7844, 1995). Human embryonic stem (hES) cells can be prepared from human blastocyst cells using the techniques described by Thomson et al. (U.S. Pat. No. 6,200,806; Science 282:1145, 1998; Curr. Top. Dev. Biol. 38:133 ff., 1998) and Reubinoﬀ et al., Nature Biotech., 18:399, 2000.

30 Cell culture methods are described generally in the current edition of Culture of Animal Cells: A Manual of Basic Technique (R. I. Freshney ed., Wiley & Sons); General Techniques of Cell Culture (M. A. Harrison & I. F. Rae, Cambridge Univ.

Press), and Embryonic Stem Cells: Methods and Protocols (K. Turksen ed., Humana Press). Tissue culture supplies and reagents are available from commercial vendors such as Gibco/BRL, Nalgene-Nunc International, Sigma Chemical Co., and ICN Biomedicals.

5 In a preferred embodiment, said BMP2 protein (also named BMP-2) is the human BMP2, more preferably a recombinant hBMP2, more preferably the human BMP2 protein having the amino acids sequence depicted in GenBank Accession Number AAF21646.

In a preferred embodiment, the CD-15 marker is the human CD-15 (also named
10 “SSEA1” marker, “SSEA1” for “Stage Specific Embryonic Antigen 1”).

Angiogenic growth factors such as fibroblast growth factors (FGFs) and vascular endothelial growth factors (VEGFs) are currently targets of intense efforts to inhibit deregulated blood vessel formation in diseases such as cancer. FGFs and VEGFs exert
15 their effects via specific binding to cell surface-expressed receptors equipped with tyrosine kinase activity. Activation of the receptor kinase activity allows coupling to downstream signal transduction pathways that regulate proliferation, migration and differentiation of endothelial cells. Inhibitors of tyrosine kinase activity such as the tyrosine kinase activity of FGF and/or VGR receptor are currently in clinical trials.

20 The inventors have surprisingly demonstrated that such receptor tyrosine kinase (RTK) inhibitor, particularly FGFR inhibitor or multitargeted tyrosine kinase receptor inhibitors, particularly resulting to the inhibition of the tyrosine kinase activity of the VEGF receptor (R-1 and/or R-2), and/or fetal liver tyrosine kinase receptor 3 (FLT3), and/or KIT (stem-cell factor [SCF] receptor), and/or PDGFR α , and/or PDGFR β , can be
25 used in step b) to improve, likely by a synergic effect with BMP2, the differentiation of primate ES cells or embryonic-like state cells in cardiovascular progenitors cells.

In a preferred embodiment, the RTK inhibitor is selected from the group consisting of SU5402 and SU11248.

The SU5402 compound has the following formula:

30 3-[3-(2-Carboxyethyl)-4-methylpyrrol-2-methylidenyl]-2-indolinone.

SU5402 inhibits the tyrosine kinase activity of fibroblast growth factor receptor 1 (FGFR1); (IC₅₀ = 10 - 20 μ M in the presence of 1 mM ATP). It also inhibits aFGF-

induced tyrosine phosphorylation of ERK1 and ERK2 ($IC_{50} = 10-20 \mu M$). SU5402 is considered as only a weak inhibitor of tyrosine phosphorylation of the PDGF receptor and does not inhibit phosphorylation of the insulin receptor. It does not inhibit the kinase activity of the EGF receptor (Mohammadi M. et al., 1997, Science 276, 955).

5 The SU11248 compound (also referenced as “Sunitinib malate” or SUTENT™) has the following formula:

N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide.

10 Sunitinib (sunitinib malate; SU11248; SUTENT™; Pfizer Inc, New York, NY) is a multitargeted RTK inhibitor with antitumor and antiangiogenic activities. Sunitinib has been identified as a potent inhibitor of VEGFR-1, VEGFR-2, fetal liver tyrosine kinase receptor 3 (FLT3), KIT (stem-cell factor [SCF] receptor), PDGFR, and PDGFR β in both biochemical and cellular assays (Faivre et al., Journal of Clinical Oncology, Vol. 24, N° 1, 2006: pp. 25-35).

15 When the SU5402 compound is used as FGF inhibitor in step b), it is preferred that the primate ES cells or embryonic-like state cells, particularly the human ES cells (HES) or human embryonic-like state cells were treated in step b) for respectively 48 hrs and 6 days with a BMP2 concentration of 10 ng/ml medium (± 5 ng/ml) in the presence of 1 μM SU5402 ($\pm 0.5 \mu M$). Following the 6 days treatment with 10 ng/ml
20 BMP2 and 1 μM SU5402, the embryonic-like state cells (iPS cells) can be trypsinised.

One of the problems which have to be solved in this context, when production of therapeutical cells is wished to commit primate ES cells or primate embryonic-like state cells toward a cardiac lineage, is to have further at one's disposal compounds used in
25 the production method, such as RTK inhibitor, which have been already used as therapeutical compound. Indeed, these compounds are known not to have relevant side-effects and generally, available as clinical grade compound.

After demonstrating the synergic effect of FGF inhibitor in step b) for differentiating the primate ES cells or primate embryonic-like state cells in cardiac
30 progenitor cells (or early cardiovascular progenitors cells having the capability to proliferate and repopulate the postinfarction scar after administration to the patient), the inventors have demonstrated surprisingly that it will be possible to use a multitargeted

RTK inhibitor available as clinical grade, such as the SU11248, as synergic compound in step b) in place of the FGF inhibitor.

Preferably, when a multitargeted RTK inhibitor, such as SU11248, is used in place of a FGF inhibitor, it is preferred that the primate ES cells or primate embryonic-like state cells, particularly from human, were treated with about 5 times more quantity of such in step b) for 48 hrs with a BMP2 concentration of 10 ng/ml medium (± 5 ng/ml) in the presence of 5 μ M SU (± 2 μ M).

In a preferred embodiment the invention provides a method for preparing a substantially pure population of progenitor cells which is at least about 80 %, preferably 85 %, 90 %, 95 %, 97 %, 98 % and 99 % pure cardiac progenitor cells which display at their surface the marker CD-15 and, preferably, which retain their capability to proliferate and repopulate the postinfarction scar after administration to a patient.

In step a) of the method according to the invention, medium for culturing primate ES cells or primate embryonic-like state cells allowing their proliferation and maintaining their pluripotency are well known by the skilled person.

Cell culture methods are described generally in the current edition of Culture of Animal Cells: A Manual of Basic Technique (R. I. Freshney ed., Wiley & Sons); General Techniques of Cell Culture (M. A. Harrison & I. F. Rae, Cambridge Univ. Press), and Embryonic Stem Cells: Methods and Protocols (K. Turksen ed., Humana Press). Tissue culture supplies and reagents are available from commercial vendors such as Gibco/BRL, Nalgene-Nunc International, Sigma Chemical Co., and ICN Biomedicals.

For example, it is known that primate ES cells required feeder cells for their culture, such as mouse embryonic fibroblasts, and FGF2 (bFGF) to maintain their pluripotency.

By "Feeder cells" it is intended to designate cells that are co-cultured with the primate ES cells. They provide an environment in which the primate ES cells type can grow. The culture of the primate ES cells can be supported by primary mouse embryonic fibroblasts (MEF) or primary human foreskin fibroblasts as exemplified. Immortalized mouse embryonic fibroblasts or human foreskin fibroblasts cells can also be used as feeder cells.

For example of basic medium which can be used for culturing primate ES cells or primate embryonic-like state cells, the KOTM-DMEM medium from Invitrogen (or from Gibco, Rockville, MD, USA) can be cited.

It is preferred that FGF2 (fibroblast growth factor 2, also named bFGF) is added
5 to the basic medium after a period of at least an overnight with ES cell or embryonic-like state cells basic medium without FGF2 on feeder cell layer.

It is preferred that the culture medium is changed every day.

Generally, the cell colonies are dissociated into single cells or small cell clusters every 4-5 days using trypsin or collagenase depending on the primate ES cells or
10 primate embryonic-like state cells source (monkey or human source).

It is preferred to never let the ES cells or primate embryonic-like state cells colonies reaching confluency in the dish.

In step a) of the method according to the invention, the medium for culturing
15 primate ES or primate embryonic-like state cells comprised a basic medium, such as the KOTM-DMEM medium, supplemented with platelet lysate obtained from primate blood, preferably from human blood.

Preferably, the platelet lysate is a total human freeze-thawed platelet lysate, more preferably at a concentration range of 5 % to 15 % (V/V), the most preferred at a
20 concentration of 7.5 % (V/V) $\pm$ 2.5 % in the basic medium.

The inventors have demonstrated that the use of platelet lysate in place of the FBS (foetal bovine serum) content usually present in the basic medium at this stage of a culture of primate ES cells or primate embryonic-like state cells allows to obtain the proliferation of non-differentiated primate ES cells or primate embryonic-like state
25 cells, the use of such platelet lysate allowing the maintain of the pluripotency of the primate ES cells or primate embryonic-like state cells obtained after this step of proliferation or propagation.

One of the benefit of platelet lysate used in place of FBS is to eliminate the problem of possible contamination of FBS with infectious microorganism, virus or
30 prion and thus to produce therapeutical cells composition with a better safety.

The blood platelet lysate can wholly or partly replace foetal bovine serum in cell culture.

To obtain such a platelet lysate, the whole blood is for example separated into red blood corpuscles and platelet-rich plasma by centrifugation suitably at about + 4°C.

Subsequently the platelet-rich plasma can be concentrated by ultrafiltration, after which the concentrated platelet-rich plasma is optionally frozen for storage and/or
5 analysis and further lysis of the platelets included. After optional freezing, the frozen plasma is thawed, preferably at a temperature below 37°C, more preferred below 20°C.

After or before thawing of the concentrated platelet-rich plasma, water can be added for accelerate the total lysis of the platelets included if necessary.

The PRP may use the patient's own plasma and/or platelets who will receive the
10 therapeutical cells. The platelets may be present in the plasma or PRP at a range of from about 200,000 to 2,000, 000 platelets per cubic centimetre, or more. The PRP may be obtained using autologous but also allogenic, or pooled sources of platelets and/or plasma from a variety of primate sources, including human sources.

In step b) of the method according to the invention, the basic medium for
15 differentiating primate ES cells or primate embryonic-like state cells can be selected for example in the group consisting of RPMI or DMEM medium.

In a preferred embodiment, the primate stem cells or embryonic-like state cells, can be treated for respectively 96 H and 6 days with 10 ng/ml BMP2 in RPMI supplemented with 2 % B27, and: 1 µM SU5402 (research grade) or 5 µM SU11248,
20 SUTENT™(clinical grade).

It is preferred that the cells do not reach confluency at the end of BMP2 treatment. It is also preferred that BMP2 is added as soon as small colonies of ES cells appear.

The invention also includes a substantially purified population of cardiac
25 progenitor cells susceptible to be obtained by the method of the present invention, wherein the cardiac progenitor cells display at their membrane surface the CD15 marker and, preferably retain their capability to proliferate and repopulate the postinfarction scar when administrate to a patient in need thereof.

In certain embodiment, the cells of the cardiac progenitor cells population
30 according to the present invention express the early mesodermal Brachyury and Tbx6 markers, the cardiac Tbx20 and Mef2c markers, the GATA4, Nkx2.5, Isl1, Tbx18 markers and the Oct-4A marker.

Preferably, by substantially purified population is meant that greater than about 80 % of the cells are cardiac progenitor cells, preferably greater than about 90 %, more preferably greater than about 95 %, more preferably yet greater than about 98 % and most preferably greater than about 99 %.

5 The substantially purified population of cardiac progenitor cells of this invention is useful for many clinical applications, preferably as a therapeutical composition or a medicament.

10 The invention particularly concerns the use of the purified population of primate cardiac progenitor cells of this invention, preferably a population of human cells, for preparing a therapeutic composition for replacing or regenerating cells or tissues in a primate, particularly cardiac cells. In particular, the invention concerns the use of a population of human cardiac progenitor cells of this invention differentiated from human embryonic stem cells for treating heart failure in a human.

15 The invention further comprised a method for selectively separating cardiac progenitor cells from a primate cells population containing non-differentiated (pluripotency) ES cells or (non-differentiated) embryonic-like state cells and cardiac progenitor cells, or a method for enriching a primate cells population cell in cardiac progenitor cells wherein said method comprises the following steps of:

20 A) contacting the cells population with anti-CD15 antibodies; and
B) selecting the cells that bind specifically to the CD15 antibodies or eliminating the cells which are not bound the anti-CD15 antibodies, said cells having the capability to specifically recognize and to bind the CD15 antibodies being the primate cardiac progenitor cells which are desired to be kept in the cells population.

25 Preferably, in step A), the anti-CD15 antibodies are anti-human CD15 antibodies, most preferably, monoclonal antibodies.

30 In a preferred embodiment, the anti-CD15 antibodies are labelled, more preferably with a marker which can be used to select and to separate the cells displaying the CD15 marker from a cells population, preferably from a cells population obtained or susceptible to be obtained by the steps a) and b) of the method for the preparation of a population of cardiovascular progenitors cells from primate ES cells or embryonic-like state cells according to the present invention.

More preferably, said antibody marker is a fluorescent marker such as FITC.

In another preferred embodiment, the anti-CD15 antibodies are bound at the surface of magnetic beads or articles or coupled to magnetic compounds.

Method using magnetic beads or particles is usually implemented for sorting cells. Antibodies specific for a particular cell of interest are covalently bond to magnetic
5 particles. They then incubate a mixture of cells in a solution with the magnetic antibodies. The entire reaction mixture is exposed to a magnetic field, which retains the cells of interest. Some of these particles are even composed of materials that naturally degrade without adversely affecting cell function. Such a system to separate or enrich
10 population in specific cell is well known from the skilled man (see BD Biosciences system, (San Jose, CA USA); positive cells selection with the MidiMACS™ separation system from Miltenyi Biotech (Bergisch Gladbach, Germany), Polysciences or Dynal Biotech)).

As alternatives in cell separation, the well established fluorescence-activated
15 cells sorting (FACS) technique can be also used (Flow cytometers can measure and separate up to 500,000 cells per minute).

The invention further includes a kit useful for enriching for cardiac progenitor cells from a cells population containing non-differentiated primate ES cells or (non-
20 differentiated) embryonic-like state cells, and cardiac progenitor cells. The kit includes anti-CD15 antibodies, preferably anti-human CD15 antibodies.

Preferably, monoclonal antibodies are used.

Preferably, the anti-CD15 antibodies are labelled, more preferably with a marker which can be used to select and to separate cells displaying the CD15 marker from a
25 cells population, preferably from a cells population obtained or susceptible to be obtained by the steps a) and b) of the method according to the present invention.

More preferably, said antibody marker is a fluorescent marker such as FITC.

In another preferred embodiment, the ant-CD15 antibodies are bound at the surface of magnetic beads or coupled to magnetic compounds.

30 Preferably, instructions are provided which have information to the user regarding the use of the antibodies for enriching for cardiac progenitor cells from the cells population.

In certain embodiments, the kit also contains magnetic beads, e.g., superparamagnetic microparticles. The magnetic beads can be complexed to the anti-CD15 antibodies, or they can be separate. The kit also can include an electromagnet for use in generating a magnetic field.

5 In another aspect, the present invention is directed to a method for proliferating or propagating primate ES cells or embryonic-like state cells, particularly human cells, maintaining their pluripotency feature during this step of proliferation or propagation, said primate ES cells or embryonic-like state cells being usually cultivated in a medium supplemented with foetal mammal serum, such as FBS, characterized in that said foetal
10 serum is replaced by a platelet lysate from a primate, preferably a human platelet lysate, preferably at a concentration of 7.5 % (V/V) $\pm$ 2.5 %.

A composition or a culture medium used for culturing cells, preferably primate ES cells, comprising BMP2 and a RTK inhibitor.

Preferably the RTK inhibitor is a FGF inhibitor or a multitargeted RTK inhibitor
15 capable to inhibit VEGFR, FLT3, KIT and/or PDGFR.

More preferably, the RTK inhibitor is selected from the group consisting of SU5402 and SU11248.

Preferably, the composition or the medium contains 10 ng/ml BMP2 ($\pm$ 5 ng/ml) for 1 μ M SU5402 ($\pm$ 0.2 μ M).

20 Preferably, the composition or the medium contains 10 ng/ml BMP2 ($\pm$ 5 ng/ml) for 5 μ M SU11248 ($\pm$ 2 μ M).

Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

25 **Legends of the figures**

Figure 1: Beating activity of I6 HES cells-derived EBS at day 30. Cells are treated for 48 H with BMP2 prior to the generation of EBs. AN EB is scored as positive if it features at least three beating areas. Data are expressed as mean (blue bars) $\pm$ SEM (pink bars) (n = 3 experiments).

30 **Figure 2:** FACS analysis of CD15 positive cells. Cells are treated for 4 days with BMP2 and SU5402 in RPMI/B27 medium. Cells are then washed once with D-PBS, incubated for 3 min with trypsin. Cells are spun down and resuspended in D-PBS

supplemented with 3 % Foetal calf serum containing the anti-CD15-FITC antibody used at a dilution of 1/100. Cells are incubated for 30 min at 4°C before FACS monitoring. The figure is representative of 3 experiments using HUES-24 or ORMES cell lines. Data are expressed as mean $\pm$ SEM.

5 **Figures 3A, 3B, 3C and 3D:** Gene expression profile of CD15-positive cardiovascular progenitors.

After sorting out the CD15-positive primate ES cells using the MACS system, cells are lysed and RNA extracted. Gene expression is monitored by real time quantitative PCR. The figure 3A is representative of 3 experiments using HUES-24 or ORMES cell lines.

10 Data are expressed as mean $\pm$ SEM and normalised to the CD15- cell population.

After sorting out the CD15-positive primate ES cells using the MACS system following checking expression of CD15 by FACS (Fig. 3B), cells are lysed and RNA extracted. Gene expression is monitored by real time quantitative PCR. The figures 3C and 3D are representative of 5 experiments using HUES-24, I6, HUES-9 or ORMES cell lines.

15 Data are expressed as mean $\pm$ SEM and normalised to the CD15- cell population.

Figures 4A and 4B: Figure 4A: Immunofluorescence of HUES cells cultured for 10 passages in clinical grade medium. The antibodies used are: anti Oct-4, TRA-1-60 and SSEA-4. Figure 4B: Real time PCR monitoring of pluripotency genes expression in HUES cells cultured for 10 passages in clinical grade medium.

20 **Figure 5:** Comparison of mesodermal and cardiac gene expression in HUES-1 and I6 cells. RNA was extracted and reverse transcribed from undifferentiated HUES-1 (passages 22-25) and I6 cell lines (passages 27-32) cultured for at least 5 passages after thaw-out on MEF prior to stimulation with BMP2. Differentiated colonies were cut out the plate before RNA extraction. Gene expression was estimated by real-time PCR and
25 expressed as a ratio between expression in I6 and expression in HUES-1. Data are normalised to β -tubulin expression and expressed as means $\pm$ SEM (n=3). * Statistically significant ($p \leq 0.01$).

Figures 6A and 6B: Figure 6A: HUES-1 and I6 cells were treated for 48 hrs with 10 ng/ml BMP2 in the presence or absence of FGF inhibitor SU5402 and RNA
30 extracted and reverse transcribed. Gene expression was monitored by real-time quantitative PCR. Results are expressed as fold stimulation in gene expression when compared to untreated ES cells. Figure 6B: HUES-1 cells treated or not with BMP2 and

SU5402 were allowed to aggregate to form embryoid bodies (EB). EBs were kept in suspension for 5 days before RNA extraction and real time PCR. Data are normalised to β -tubulin expression and expressed as means $\pm$ SEM (n=3-5). * Statistically significant ($p \leq 0.01$).

5 **Figure 7:** BMP2-treated HES cells were engrafted into postmyocardial infarcted rats and their fate was examined two months later by real time PCR of α -actin mRNA following reverse transcription of mRNA extracted from myocardial sections. The figure shows both the profile of the melting curves of amplicons and the amplicons on gel. Human RNA was used as a positive control. * Statistically significant ($p \leq 0.01$).

10 **Figures 8A, 8B, 8C and 8D:** Immunostaining of cryosections from HES cell-engrafted myocardium using an antihuman lamin antibody (Fig. 8A) (note that the anti-lamin antibody stained HES-derived cells within the scar area but not the surrounding endogenous rat cells) and an anti-human β -myosin antibody (Fig. 8B). The antibody did not recognize the adult rat endogenous β -MHC (left panel B) while it bound human β -
 15 MHC. Images were acquired in confocal microscopy. (Fig. 8C) quantification (in %) of the human β -MHC positive regions in the scars of myocardium engrafted with BMP2- or BMP2 with SU5402-treated HUES-1 or BMP2-treated I6 cell lines: * Statistically significant ($p \leq 0.025$). The area of β -MHC positive area within the scar was calculated using the threshold function of Metamorph software (fig. 8D) a transversal section
 20 stained by the anti- β myosin antibody revealed some sarcomeric structures. The size was calculated using the scaling system of the ZEISS software driving the confocal microscope.

Figure 9: Eosin-Hematoxylin stained section from HES cell-engrafted myocardium. The scar area does not show any sign of cell infiltration or cell proliferation.

25 **Figures 10A and 10B:** IPS cells give rise to CD15+ cardiovascular progenitors, CD15+ iPS cells were generated and sorted following 6 days BMP2 treatment

- Figure 10A: FACS analysis of cardiac markers in CD15+ cells.

- Figure 10B: Immunofluorescence of CD15+ cells cultured for 5 days on MEF. The scale bar indicates 10 μ m.

30 **Figures 11A, 11B and 11C:** CD15+ cells express cardiac, endothelial and vascular proteins markers; CD15+ sorted cells were cultured for 5 days on MEF and immunostained with the indicated markers; some cells were treated with VEGF or

PDGF and immunostained with anti smooth muscle actin and myosin or CD31. Some others were cultured with human fibroblast isolated from the myocardium and stained with an anti-actinin antibody.

5 Materials and Methods for Examples 1-3

vitrogen cat n° 10829018)

Knockout™ SR serum replacement (cat n° 10828028 Invitrogen) test batch before using:

Trypsin 0.05 %/0.5 mM EDTA4Na 1X (Invitrogen cat n° 25300054)

10 Glutamax 200 mM (Invitrogen cat n° 35050038)

MEM Non essential Amino Acids solution (200 mM) (Invitrogen cat n° 11140035)

Mercaptoethanol (Invitrogen cat n° 31350010) (make solution at 10^{-7} M in PBS and use for one month)

RPMI 1640 with glutamax (Invitrogen cat n° 61870-010)

15 F12 nutrient supplement with glutamine (Invitrogen cat n° 21765-029)

Dulbecco Phosphate Buffered Saline (D-PBS) Ca- and Mg-free (Invitrogen cat n° 14200067)

B27 50X supplement without vitamin A (Invitrogen cat n° 12587010)

Gelatin 2 % solution from bovine skin cell (Invitrogen cat n° G1393-100ml)

20 Mitomycin 2 mg Sigma cat n° M4287)

FGF2 (Human recombinant, preprotech cat n° 100-18B)

BMP2 (Human recombinant R&D system)

Dispase™ (Invitrogen cat n° 17105041)

collagenase CLS2 (Invitrogen cat n° 17104-019)

25 SU5402 (calbiochem cat n° 572630)

CD15 microbeads (MACS sorter Miltenyi cat n° 130-046-601)

Anti-SSEA4 and anti-TRA 1-60 (Chemicon cat n° 90231 and 90232, respectively)

Anti-Oct-4 (Santa Cruz, cat n° sc-9081)

anti-CD15-FITC antibody from BD Bioscience (IgM clone MMA cat n° 340703)

30 RNA extraction kit (Mini RNA Isolation II Kit™ Zymo Research, cat n° R1033)

Real time PCR reagent: LightCycler® FastStart DNA MasterPLUS SYBR Green I (Roche cat n° 3515885)

Equipment

Low attachment dishes (NUNC™ Low Cell Binding Plates cat n° 1453)

Sterile cell culture dishes and pipettes

5 500 ml Filtration unit 0.2 µm Nalgene cat n° 162-0020

A real time QPCR thermocycler (Roche LightCycler 1.5)

Example 1: Culture of primate ES cells

Primate ES cell lines require feeder cells (Mouse Embryonic Fibroblasts (MEF)
10 prepared from E14 mouse embryos) and FGF2 to maintain their pluripotency.

1- MEF are cultured for 3 or 4 passages and treated for 2 hours with 10 µg/ml mitomycin; cells are washed twice with PBS, trypsinised for 5 min and plated in gelatin (0.1 %)-coated plates at a density of 40,000 cells/cm².

2- Primate embryonic stem cells are thawed out quickly in warm propagation medium,
15 spun down at 800 rpm for 4 min, and resuspended to be plated on feeder cells cultured overnight with ES cell medium without FGF2. Add FGF2 to the plate.

3- Rhesus ES cells (ORMES-2 given by Dr S Mitalipov, Dr Wolf's laboratory) and Human ES cell lines HES cell lines from D Melton's laboratory [39] and I6 cell lines from the Technion Institute [40] (NIH approved) are then cultured on MEF using
20 KO™-DMEM medium supplemented with mercaptoethanol, glutamine, non essential amino acids, 15 % KOSR and 10 or 5 ng/ml FGF2 respectively (see Table 1). For Rhesus ES cells [41], 20 % of F12 medium supplements the KO™ -DMEM.

4- Medium is changed every day.

5- Cell colonies are dissociated into single cells or small cell clusters every 4-5 days
25 using trypsin (HUES) or collagenase (I6, ORMES-2, 6, 9, 18), respectively (see paragraph "BOX1").

It is preferred to never let the ES cells colonies reaching confluency in the dish. Split them at about 70 % confluency.

30 **Example 2: Protocol to direct the fate and to differentiate primate ES cells toward a cardiac lineage**

1- Primate ES cells are treated one or two days following the passaging for 48 H with 10 ng/ml BMP2 in the presence of 1 μ M SU5402 a FGF receptor inhibitor, in KOTM-SR DMEM. It is critical that the cells do not reach too much confluency at the end of the treatment.

5 It is preferred to resuspend BMP2 at 1 mg/ml in aqueous buffer containing at least 0.1 % BSA to prevent adsorption to the vial at pH 5 or lower (due to its low solubility at neutral pH) and stored as aliquot at -20°C. Frozen stocks at 10 μ g/ml can be further made in PBS. Do not freeze/thaw.

2- Embryoïd bodies are generated after dispase used at 1 mg/ml for 15 min at 37°C
10 (HUES1, 9, 24, 26) or collagenase CLS2 (16) dissociation of HUES cell colonies and cell aggregation in low attachment dishes in KOTM-DMEM, 5 % SR. $6 \cdot 10^6$ to 10^7 cells are required to fill a low attachment B6 plate to allow for formation of EBs.

15 It is preferred to use mechanical cell dissociation after dispase or collagenase step with a 5 ml pipette to generate small (20-50 cells) cell clusters. Spin down the cells and resuspend them in 5 % SR-KOTM-DMEM (Differentiation medium).

3- The functional index of cardiac differentiation *in vitro* is the score of beating EBs, observed after 3-4 weeks (Figure 1). At earlier days, the kinetic of HES cell differentiation is monitored by real time PCR of cardiac transcription factors [42]. *In vivo* experiments (i.e., cell xenograft in immuno-compromised postmyocardial infarcted
20 rats) also serves as a functional index of cardiomyocytes derived from this protocol [42].

Generation and selection of cardiovascular progenitors

1- Primate stem cells are treated for 96hrs with 10 ng/ml BMP2 in RPMI supplemented
25 with 2 % B27, and (1 μ M SU5402 (research grade) or 5 μ M SU11248, SUTENTTM (clinical grade)).

It is preferred that the cells do not reach confluency at the end of BMP2 treatment. It is also preferred that BMP2 is added as soon as small colonies of ES cells appear.

30 2- Use FACS analysis using an anti-CD15-FITC antibody to visualize SSEA-1 (CD15) positive cells (Figure 2). Cells can thus be sorted out using CD15-coated Miltenyi beads (Kit) as follows.

- 3- Cells are trypsinized and filtered on a 70 μ m mesh nylon filter.
- 4- Cells are incubated for 30 min at 4°C with gentle occasional agitation with anti-CD15 antibody-coated Miltenyi beads (100 μ l/ $5 \cdot 10^6$ cells) in PBS supplemented with 0.5 % BSA and 2 mM EDTA.
- 5 5- Cells are transferred to a L50 Miltenyi cartridge set on the magnet.
- 6- Cells are washed three times with 3 ml D-PBS- BSA/EDTA and allowed to be eluted from the column removed from the magnet using 3 ml of D-PBS/BSA/EDTA. The cells which go through are recycled to the cartridge on the magnet and eluted once more. This procedure is repeated three times. Counting the cells revealed 50-60 % of CD15
- 10 positive cells.
- 7- Gene expression profile is performed by RT-real time Q-PCR (see paragraph "BOX2"). A phenotypic analysis of the CD15-positive cells revealed that they express early mesodermal (Brachyury, Tbx6) and cardiac and cardiovascular (Tbx20, Mef2c, GATA4, Isl1, Tbx18, Flk1) markers (Figures 3A-3D) Nkx2.5 was absent in the CD15
- 15 negative while detected in the CD15 positive cell population. The CD15 positive cell population loses expression of pluripotency gene (Lefty, Nanog, Crypto). However, this cell population still over-expresses Oct-4A [43, 44].

When cultured on MEF, CD15-positive cells retained the phenotype of cardiovascular progenitors as monitored by immunostaining cardiovascular markers;

20 when treated with VEGF (10 or 50 ng/ml) or PDGF (10 or 50 ng/ml), CD15+ become endothelial and smooth muscle cells respectively. When cultured on human cardiac fibroblasts, CD15+ cells differentiate into actinin- positive cardiomyocytes.

Example 3: Culture of primate ES cells in a clinical grade medium

25 Embryonic stem cells are cultured on irradiated adult human skin fibroblasts (FSBT from Dr O. Damour, Hôpital E Herriot, Lyon) in KOTM-DMEM supplemented with:

- 7.5 % of total human freeze-thawed platelet lysate,
- heparin (1000 UI/ml)
- 30 10 ng/ml FGF2 and insulin
- 10 passages in such a medium do not affect expression of markers of pluripotency (Figures 4A-4B).

FSBT are cultured in DMEM glutamine supplemented with 10 % foetal calf serum (batch approved by AFSSAPS).

Table 1: Propagation and differentiation medium HES cells

5

	KnockOut™-DMEM	400 ml or KO™-DMEM 320 ml + 80 ml F12 (ORMES)
	Glutamine 200 mM	5 ml
	Non essential amino acid 100 mM	5 ml
10	MercaptoEthanol 1x10 ⁻⁴ M	500 µl (<i>Use the stock 10⁻⁴ M solution for one month only</i>)
	Serum replacement	15 % (5 % for cell differentiation)
	Medium is filtered on 0.2 µm Nalgene Filter unit	
	FGF2 (for ESC propagation only)	5 or 10 ng/ml

15

Human PCR primer sequences (See Tables 2 and 3, Example 4)

BOX 1: Cell passaging

It is preferred that all media, enzymes, PBS should be warmed up at 37°C.
20 Primate ES cells are very sensitive to change in temperature and should remain as long as possible at 37°C.

ORMES splitting: replace the culture medium by KO™-DMEM with 1 mg/ml collagenase (500 µl or 2.5 ml is enough for one well of a 6wells dish or for a B10 plate). Incubate the plate at 37°C for 5 min. Add 1 or 5 ml propagation medium without FGF2
25 and scrape the cells with a 5 ml pipette. Transfer the cells to a 15 ml falcon tube and spin them down at 800 rpm for 4 min at RT. Aspirate the supernatant and resuspend the cells with propagation medium with FGF2. Break down the ES cells colonies by pipetting them forth and back 3 to 5 times until getting a homogenous cell suspension. Plate the cells 1/6.

30 I6 cell line splitting: use the same protocol as above but incubate the cells in the presence of collagenase for 45 to 60 min.

HUES cells splitting: Wash the cells once with warm PBS and add trypsin (500 µl or 2.5 ml is enough for one well of a 6wells dish or a B10 plate). Incubate the cells under the hood for exactly 3 min. Wash out trypsin and resuspend the cells with propagation medium slightly by flushing out the feeder cell layer. Plate the cells at 1/6.

5

BOX 2: RT-PCR and real time quantitative PCR

Total RNA is prepared after cell lysis using a kit (Zymo research). After reverse transcription using the reverse transcriptase Superscript 2TM (Invitrogen) according to the manufacturer instructions, Real time PCR is carried out using a set of gene specific primers (see Tables 2 and 3). 2-6 ng cDNA is used for real time quantitative PCR, performed with a lightcycler1.5 and the SYBR Green fast start kit (Roche, Germany). The 12-µl reaction mix contained 1 µl of Master SYBR Green I mix, including Taq DNA polymerase, buffer, deoxynucleoside trisphosphate mix, SYBR Green I dye, 3 mM MgCl₂ and 0.5 µM of each primer. 2 µl of 10-fold diluted cDNA is added to the mixture. Data are normalised using RT-PCR of the GAPDH mRNA as an index of human cDNA content after reverse transcription. Amplification includes an initial denaturation at 95°C for 8 min, and 45 cycles of denaturation at 95°C for 3 s, annealing at 65°C for 8-10 s, and extension at 72°C for 7-10 s. The temperature transition rate is 20°C/s. Fluorescence is measured at the end of each extension step. After amplification, a melting curve is acquired by heating the product at 20°C/s to 95°C, then cooling it at 20°C/s to 70°C. The reaction was maintained at 70°C for 20 s followed by slow heating at 0.3°C/s to 95°C. Melting curves are used to determine the specificity of PCR products, and they are further confirmed by gel electrophoresis.

25 **Example 4: Differentiation in vivo of cardiac committed Human embryonic stem cells in post-myocardial infarcted rats**

A) Materials and Methods

Real-Time Quantitative PCR by SYBR Green Detection

RNA was extracted from HES cells or slices of rat myocardium using a Quiagen kit. One µg of RNA was reverse-transcribed using the Mu-MLV reverse transcriptase (Invitrogen, Cergy, France) and oligo(16)dT.

30

Real-time quantitative PCR was performed using a Light Cycler (Roche Diagnostic) or a Chromo4 thermal cycler (Biorad). Amplification was carried out as recommended by the manufacturers. Twelve or Twenty two μ l reaction mixture contained 10 or 20 μ l of Roche or Abgene SYBR Green I mix respectively (including
5 Taq DNA polymerase, reaction buffer, deoxynucleoside trisphosphate mix, and SYBR Green I dye, 3 mM $MgCl_2$), 0.25 μ M concentration of appropriate primer and 2 μ l of cDNA. The amplification programme included the initial denaturation step at 95°C for 15 or 8 min, and 40 cycles of denaturation at 95°C for 10 s, annealing at 65°C for 8 s (Light cycler) or 20 s (Chromo4), and extension at 72°C for 8 or 30 s. The temperature
10 transition rate was 20 (Light Cycler) or 4 (Biorad)°C/s. Fluorescence was measured at the end of each extension step. After amplification, a melting curve was acquired by heating the product at 20 or 4°C/s to 95°C, cooling it at 20 or 4°C/s to 70°C, keeping it at 70°C for 20 s, and then slowly heating it at 20 or 4°C/s to 95°C. Fluorescence was measured through the slow heating phase. Melting curves were used to determine the
15 specificity of PCR products, which were confirmed using conventional gel electrophoresis. Data were analysed according to Pfaffl et al. [16]. Primers specific for human genes are described in Tables 2 and 3.

Table 2: PCR primer sequences Table 2: PCR primer sequences

Genes	Forward (SEQ ID NO:)	Reverse (SEQ ID NO:)
β -tubulin	CCGGACAGTGTGGCAACCAGATCGG (1)	TGGCCAAAAGGACCTGAGCGAACGG (2)
Nkx2.5	CATTTACCCGGGAGCCTACG (3)	GCTTTCCGTCGCCGCCGTGCGCGTG (4)
Mef2c	AGATACCCACAACACACCACGCGCC (5)	ATCCTTCAGAGAGTTCGCATGC (6)
SRF	CTCCGCCCCGCTCAGACCCCACCACAGA (7)	AGGTAGTTGGTGATGGGGAAGGA (8)
α -actin	CTATGTCGCCCTGGATTTTGAGAA (9)	TGAGGGAAGGTGGTTTGGAAGAC (10)
Oct-4	ACGACCATCTGCCGCTTTGAG (11)	GCCTCTCACTCGGTTCTGAT (12)
Tbx6	AGGCCCCGCTACTTGTTTCTTCTGG (13)	TGGCTGCATAGTTGGGTGGCTCTC (14)
Isl1	CATCGAGTGTTCGCTGTGTAG (15)	GTGGTCTTCTCCGGCTGCTTGTGG (16)
FoxH1	GCCCCTGCCACGCTGTCTA (17)	GGTACCTCTTCTTCCTCCTCTT (18)
Brachyury	CGGAACAATTCTCCAACCTATT (19)	GTACTGGCTGTCCACGATGTCT (20)
Mesp1	CTCGTCTCGTCCCCAGACT (21)	AGCGTGCGCATGCGCAGTT (22)
Tbx20	CTGAGCCACTGATCCCCACCAC (23)	CTCAGGATCCACCCCCGAAAAG (24)
Gata4	GGTTCCCAGGCCTCTTGCAATGCGG (25)	AGTGGCATTGCTGGAGTTACCGCTG (26)
Pax6	GCCAGCAACACACCTAGTCA (27)	TGTGAGGGCTGTGTCTGTTC (28)
α -FP	ACTGCAATTGAGAAACCCACTGGAGATG (29)	CGATGCTGGAGTGGGCTTTTTGTGT (30)
Cx43	TACCATGCGACCAGTGGTGCGC (31)	GAATTCTGGTTATCATCGGGGAA (32)
GAPDH	ATGGGCAAGGTGAAGGTCGGAG (33)	TCGCCCCGACTTGATTTTGCAGG (34)
Tbx5	TACCACCACACCCATCAAC (35)	ACACCAAGACAGGGACAGAC (36)
LeftyA	GGGAATTGGGATACCTGGATTC (37)	TAAATATGCACGGGCAAGGCTC (38)
TDGF1	ACAGAACCTGCTGCCTGAAT (39)	ATCACAGCCGGGTAGAAATG (40)
Nanog	CAAAGGCAAACAACCCACTT(41)	TCTGCTGGAGGCTGAGGTAT (42)

5 Table 3: PCR primer sequences: Melting T° (°C) and Genbank Reference sequence

Genes	Melting T° (°C)	Refseq ID
GAPDH	87	AF261085; NM_002046
Nkx2.5	88	AB021133
Mef2c	86	NM_002397; AL833268
Oct-4A	90	NM_002701
Tbx6	88	AJ007989; NM_004608, NM_080758
Brachyury	92	AJ001699; NM_003181
Tbx20	88	AJ237589; NM_020417
Tbx5	85	U89353; NM_080717
LeftyA	89	U81523; NM_003240
TDGF1	90	M96955; NM_003212
Nanog	84	AB093576; NM_024865
Pax6	85	AY707088; NM_001604
α -FP	88	V01514

B) Culture and cardiac commitment of Human Embryonic stem cells

HUES-1 and I6 cell lines were cultured on Mouse Embryonic Fibroblasts (MEF) prepared from E14 mouse embryos using KOTM-DMEM medium supplemented with mercaptoethanol, glutamine, non essential amino acids, 15 % KOTMSR and 10 or 5
5 ng/ml FGF2 respectively. Medium was changed every day. Cell colonies were dissociated into single cells or cell clusters every 4-5 days using trypsin (HUES-1) or collagenase (I6), respectively. A similar enzymatic digestion was used prior to cell transplantation in infarcted rats.

HES cells were treated for 48 hrs with 10 ng/ml BMP2 in the presence or
10 absence of 1 μ M SU5402, a FGF receptor inhibitor, in low KOTMSR (5 %) containing KOTM-DMEM. Embryoïd bodies were generated after trypsinisation (HUES-1) or collagenase (I6) dissociation of HES cell colonies and cell aggregation in low attachment dishes (Nunc) in DMEM, 10 % foetal calf serum.

C) Myocardial infarction model

Myocardial infarction was induced in female Wistar (mean weight of 250 g) by ligation of the left coronary artery. Rats were operated on under general anaesthesia with isoflurane (Baxter), 3 % at induction and 2 % for maintenance. After tracheal intubation, mechanical ventilation (Alphalab, Minerve) was set at a rate of 70/min and
20 with an 0.2 ml average insufflate volume. Analgesia was performed with a 10 mg/kg subcutaneous injection of ketoprofen (Merial).

The heart was exposed through a left thoracotomy and the left coronary artery was permanently snared between the pulmonary artery trunk and the left atrial appendage.

25

D) Rats randomization and myocardial cell injection

On the 15th day following infarction, the rats were reoperated on by median sternotomy and randomized to receive injections of BMP2-treated HUES-1 cells (3×10^6 HUES-1 cells, n = 11 rats) in suspension of single cells, BMP2-treated I6 ES cells (3×10^6 I6 cells, n = 11 rats) in suspension of small cell clusters or control medium (n = 9
30 rats). Additional animals (n = 5 rats) received in-scar injections of 3×10^6 HUES-1 cells that had been exposed to both BMP2 and SU5402. We selected HUES-1 cell line for the

latter experimental situation since this is the one which is not already committed to the mesoderm. One rat of each group (HUES-1 cell- and I6 cell- transplanted) died within 48 hrs after cell injection.

Immunosuppressive therapy, consisting in one daily 10 mg/kg subcutaneous shot
5 of cyclosporine A, was started on the same day and continued until sacrifice.

E) Histopathology

Myocardial sections were stained with eosin and hematoxylin using a standard protocol.

10 Two months after myocardial injection, rats were euthanized after general anaesthesia. Transverse-cut rat hearts were immediately fixed in OTC (Tissutec) and frozen at -180 °C nitrogen. Eight µm sections were cut on an ultramicrotome (LM 1850,TM Leica).

Potential tumor growth was assessed with 8 µm standardized sections stained
15 with hematoxylin and eosin.

Immunofluorescence of myocardial cryosections were performed after
paraformaldehyde fixation and permeabilisation using Triton X-100TM with an anti-human ventricular β-myosin heavy chain (MHC) (Chemicon) , anti-human lamin A/C (Novacastra) anti-atrial natriuretic peptide (ANP, Abgent) and anti-Connexin 43 (Cx43)
20 (SIGMA) antibodies. The proteins were revealed using alexa-conjugated antibodies. Sections were observed in confocal microscopy (ZEISS LSM-510TM meta).

In addition, a whole-body autopsy of each transplanted rat, including brain, lungs, liver, spleen, pancreas, kidneys, periaortic lymph nodes, thymus, spine and ovaries, was systematically performed for the detection of a tumor.

25

F) Results

1) Phenotype of undifferentiated I6 and HUES-1 cell lines

We used both HUES-1 and I6 HES cell lines to test their cardiogenic potential in vitro and in vivo. Indeed, a real-time PCR amplification of a few mesodermal and
30 cardiac genes in both cell lines showed that the I6 cell line featured a higher basal expression of both mesodermal (Tbx6, SRF, Mesp1, brachyury) and early cardiac (Isl1, Mef2c, Tbx20) genes. GATA4 was weakly expressed in I6 but not in HUES-1 cells.

Nkx2.5 was barely detected in either I6 or HUES-1 cell lines. Oct-4 level was not significantly different between both cell lines (Fig. 5).

2) Cardiac commitment of HES cells

Both I6 and HUES-1 Human ES cells were treated for 48hrs with 10 ng/ml
5 human recombinant BMP2. Gene induction was tested using real time Q-PCR. Figures 6A and 6B shows that both mesodermal (i.e., SRF, Tbx6, FoxH1, Isl1) and cardiac (Mef2c, Nkx2.5, α -actin) genes were induced by the morphogen in HUES-1 cells. This effect was further enhanced by 3-10 folds when BMP2 was added in the presence of the FGF-R inhibitor SU5402. No significant difference was observed in the extent of the
10 BMP2 cardiogenic response between both cell lines (Fig. 6A) although the total number of copies of each gene expressed following BMP2 induction was much higher (i.e. 10-15 fold) in I6 than in HUES-1 cell line (data not shown).

To test whether BMP2-induced HES cell commitment was translated into a process of cardiac differentiation and to envision the differentiation scenario that might
15 take place in vivo, control or BMP2-challenged HUES-1 cells were allowed to aggregate to form embryoid bodies (EBs). Gene expression was then monitored in day 2 and day 5 EBs. BMP2 effect was observed at day 2 (i.e. two fold induction in gene expression) and became prominent at day 5 (Fig. 6B). At that stage of development, expression of both mesodermal and cardiac genes was dramatically increased by 3 to 10
20 folds (Fig. 6). In contrast, Oct-4 was downregulated and almost absent in EBs generated from BMP2-treated ES cells. Similar results were obtained using I6 cell line.

3) Engraftment of cardiac committed cells in post-infarcted rat heart

Two months after coronary artery ligation, Human α -actin mRNAs were identified in transplanted hearts but not in those injected with the control medium (Fig.
25 7). In contrast, we could not detect any mRNA encoding Oct-4, Pax6 (an early ectodermal marker) or α -foeto protein, an early endodermal marker (data not shown).

Immunostaining with an anti-ANP and anti-human lamin antibodies revealed the presence of lamin-positive human ES cell derived-cardiomyocytes (Fig. 8A).

To further define the phenotype of ES cell-derived cardiomyocytes, sections
30 were immunostained with an anti-human β -MHC antibody. These experiments revealed the presence of differentiated cardiomyocytes (Fig. 8B) in 40 % and 71 % of cryosections examined from HUES-1- and I6-engrafted hearts, respectively and in 85 %

of sections examined from rat grafted with HUES-1 cells treated with both BMP2 and SU5402. The cell engraftment was however limited. BMP2 treated HUES-1, I6 and BMP2/SU5402 HUES-1 treated ES cell-derived cardiomyocytes colonized 2.4 ± 0.3 , 3.1 ± 0.4 and 3.6 ± 0.3 % of the scar ($n = 10$) (Fig. 8C), respectively. Careful
5 examination of these sections further indicated that these cardiomyocytes were still at a foetal stage demonstrated by a shorter sarcomeric length ($1.6 \pm 0.1 \mu\text{m}$) compared to $2 \pm 0.1 \mu\text{m}$ in adult rat (Fig. 8D).

Eosin-hematoxylin stained sections did not show any sign of inflammation or cell hyperproliferation two months posttransplantation (Fig. 9). Likewise, whole-body
10 autopsies failed to disclose any tumor in peripheral organs.

Example 5: Generation of CD15+ cardiovascular progenitors fom human iPS cell line

Human iPS cell line 111, were generated using human dermal fibroblasts
15 infected by lentivirus harbouring the cDNAs encoding Oct4, Sox2, Lin 28, Klf4 and Nanog.

Following 6 days treatment with 10 ng/ml BMP2 and 1 μM SU5402, iPS cells were trypsinised and incubated for 30 min with anti-CD15 conjugated magnetic beads (Miletenyi) and sorted out using Miltenyi columns. A fraction of BMP2-treated cells
20 were used prior to sorting for FACS analysis using the anti-CD15 FITC and anti-cardiac markers antibodies (Figures 10A and 10B). 38 % of cells turned out to be CD15 +. This percentage was used to normalise the percentage of cells positive for the cardiac markers (numbers in green). Cells were then plated on mouse embryonic fibroblasts in KODMEM added with KOSR (invitrogen), glutamine, non essential amino acids and
25 mercaptoethanol (HES propagation medium) and stained one week later with anti-is11, -Nkx2.5 and -Mef2c. A similar pattern of expression of cardiac proteins (i.e., Nkx2.5, Mef2c, Tbx5 and Isl1) as well as endothelial marker CD31 were found in CD15+ cells derived cells as assessed by FACS analysis (Figure1A) and immunofluorescence (Figure 10B).

30 Here the inventors also demonstrate that CD15+ cardiovascular progenitors could also be derived from iPS cells.

Discussion

This study reveals that HES cells or embryonic-like state cells (iPS cells) are capable to differentiate into cardiomyocytes without formation of teratomas after commitment toward a cardiac lineage using the cardiogenic factor BMP2. While BMP2
5 was shown to improve late cardiac differentiation of already differentiating cells [17], our study reports the strong instructive action of the morphogen on undifferentiated HES cells.

BMP2 is a potent mesodermal and cardiogenic instructor when used at low concentration. Its cardiogenic potential is a well conserved property throughout the
10 evolution. Dpp, the drosophila homolog of BMP2, favours formation of the mesoderm including the heart [18]. Similar effects have been observed in zebrafish [19], Xenopus [20-21] and chicken [22]. Our data obtained in two separate cell lines uncovered that BMP2 function is conserved in human species. While I6 cells were more prone to give rise to a mesodermal lineage (Fig. 5), maximal BMP2 response was not significantly
15 different from the one observed with HUES-1 cells although maximal extent of gene expression was higher in I6 than in HUES-1 cells. Used alone, in a defined (KOSR) medium, BMP2 effect was weak while its instructive action was dramatically enhanced by addition of the FGF receptor inhibitor, SU5402. Indeed, Human ES cells are grown on feeder cells which secrete many factors including FGF2 which is known to
20 antagonize the BMP2 signaling pathway. SU5402 could act through at least two mechanisms to unmask the BMP2 transcriptional effect. First, FGF2 phosphorylates smad2/3, thereby preventing the BMP2 signaling co-factor from translocating into the nucleus and thus to exert its transcriptional action [23]. Second, FGF2 is also known to act as a paracrine factor on both MEF and HES cells to regulate expression of Cerberus,
25 a nodal and BMP antagonist enriched in HES cells [24]. Finally, it might be that SU5402 blocks self-renewal of cells and favours non-specific differentiation which is further directed to the mesoderm by BMP2. By blocking all or either one of these pathways, the FGF inhibitor is required to unravel the BMP2 transcriptional response of HES cells.

30 In keeping with previous observations made in hearts transplanted with mouse [10, 11, 25], and human [26] ES cells, no hyperproliferation (teratoma) was observed in any of the rats injected with cardiac-committed HES cells. As intramyocardial injections

in a beating heart are also known to cause leakage of a substantial proportion of cells [27], it is also noteworthy that we failed to document any extra-cardiac tumor. In fact, it was known for a long time that grafts of embryonic tissue also lose the capacity to form tumors very early after differentiation [28] when they acquire control of their proliferation by extracellular signal regulated kinases. It is thus not surprising that a similar scenario takes place after cardiac commitment of HES cells. As such, our findings are not in contradiction with the previous observation [11] that injection of HES cells into a normal immunocompetent myocardium results in teratoma formation since the latter results primarily suggest that such an environment is unlikely to provide enough cardiogenic factors required for differentiation of ES cells. Of note, the rather reassuring safety data yielded by our experiments were obtained despite the lack of pretransplantation sorting targeted at eliminating non specified cells. This suggests that the environment of the diseased myocardium (i.e., scar) enriched in growth factors is sufficient to drive primed ES cells toward a cardiac fate [25]. In a clinical perspective, however, such a selection step remains a major goal.

So far, two studies have assessed the effects of intramyocardial transplantation of HES cells. Both have entailed the use of embryoid body-derived cardiomyocytes into either normal myocardium [26] or acutely infarcted myocardium [29]. To make the protocol more clinically relevant, we selected a delayed timing of in-scar transplantation that tends to mimic the clinical scenario of heart failure and injected cardiac-specified but not yet fully differentiated monolayer-cultured cardiovascular progenitors. Altogether, the engraftment patterns seen after 2 months support the advantage of this cardiac commitment process before transplantation into the target scar where local signals are then expected to drive the fate of the graft further down the cardiomyocytic differentiation pathway.

We should however point out that the phenotype of HES cell-derived cardiomyocytes in situ was rather close to a foetal one. Indeed the cells still expressed β -MHC and ANP, two known markers of early stage of cardiac differentiation. The short length of the sarcomere is still characteristic of a foetal myocyte. Several reasons could account for this immature phenotype. HES cells may require a longer time (more than two months) to fully differentiate. Alternatively, the paracrine environment of the infarction scar may not provide the factors (some FGFs, Neuregulin, retinoic acid,

BMP10, ...) [30] or signals taking place in embryogenesis to ensure a full differentiation process.

Another interesting observation is that I6 cells gave rise to larger engraftment areas than HUES-1 cells. Although both cell lines respond with the same efficiency to BMP2, I6 cells feature a higher basal expression of mesodermal cardiac genes (Fig. 5). This indicates that the cell line is already committed to the mesoderm, which is likely to account for the better cardiogenic potential in vivo. Of note, HUES-1 cells pretreated with BMP2 together with SU5402 also featured a better engraftment than HUES-1 challenged by BMP2 alone. This further emphasizes that the stage of specification is crucial to ensure a proper differentiation of ES cells in situ. The finding that the rates of scar repopulation by the grafted cells was overall low probably reflects a combination of initially insufficient cell dosing, extracardiac cell leakage at the time of injections and possible death of retained cells. Clearly, optimisation of the functional benefits of ES cells transplantation will require that each of these issues be thoughtfully addressed.

Finally, and in contrast to what has been reported in our previous studies using mouse ES cells [10, 31], we could not detect Cx43 mRNA or protein in HES cell-derived cardiomyocytes. HES-cell derived differentiated cardiomyocytes [13] did not either express Cx43 when transplanted in injured left ventricle while they did express it when co-cultured with neonatal rat cardiomyocytes [32]. The reason for this discrepancy with mouse ES cells or the ex-vivo situation is still unclear and might involve line-specific differences in the cardiogenic potential, a still early stage of cell development, a level of expression below the threshold of detection by immunostaining, a mistargeting of the protein or inhibitory signals coming from the fibrotic scar of infarcted rat myocardium to which HES cells might be highly sensitive. Finally, Human ESC were transplanted into rat hearts and that some of the cues required for the full differentiation of the cardiac-specified cells into Cx43-expressing cardiomyocytes may have been missing. This issue is under investigation in the laboratory.

Expression of Cx43 remains, however, critical to establish unequivocally as a true cardiac regeneration implies that the donor-derived cardiomyocytes can establish gap junction-supported electromechanical connections with those of the host. The formation of such a syncytium allowing graft-host synchronized beats which is critical for enhancement of contractility has not yet been achieved with adult cells, whether

myogenic [33] or bone marrow-derived [34]. The demonstration that HES cells could fill this unmet need would likely be a major step for rationalizing their use in situations where patient outcomes are critically dependent on the replenishment of a new pool of contractile cells.

REFERENCES

- [1]. Beltrami AP, Urbanek K, Kajstura J, Yan SM, Finato N, Bussani R, Nadal-Ginard B, Silvestri F, Leri A, Beltrami CA, Anversa P. Evidence that human cardiac myocytes divide after myocardial infarction. *N Engl J Med.* 2001, 344:1750-7.
- 5 [2]. Janssens S, Dubois C, Bogaert J, Theunissen K, Deroose C, Desmet W, Kalantzi M, Herbots L, Sinnaeve P, Dens J, Maertens J, Rademakers F, Dymarkowski S, Gheysens O, Van Cleemput J, Bormans G, Nuyts J, Belmans A, Mortelmans L, Boogaerts M, Van de Werf F. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised
10 controlled trial. *Lancet*, 2006, 367:113-21.
- [3]. Meyer GP, Wollert KC, Lotz J, Steffens J, Lippolt P, Fichtner S, Hecker H, Schaefer A, Arseniev L, Hertenstein B, Ganser A, Drexler H. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation
15 infarct regeneration) trial. *Circulation*, 2006, 113:1287-94.
- [4]. Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, Endresen K, Ilebekk A, Mangschau A, Fjeld JG, Smith HJ, Taraldsrud E, Groggaard HK, Bjornerheim R, Brekke M, Muller C, Hopp E, Ragnarsson A, Brinchmann JE, Forfang K. Intracoronary injection of mononuclear bone marrow cells in acute myocardial
20 infarction. *N Engl J Med.*, 2006, 355:1199-209.
- [5]. Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Suselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. *N Engl J Med.*n 2006, 355:1210-21.
- 25 [6]. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. *Nature*, 2004, 428:668-73.
- [7]. Murry CE, Soonpaa MH, Reinecke H, Nakajima H, Nakajima HO, Rubart M, Pasumarthi KB, Virag JJ, Bartelmez SH, Poppa V, Bradford G, Dowell JD, Williams
30 DA, Field LJ. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. *Nature*, 2004, 428:664-8.

- [8]. Rosenzweig A. Cardiac cell therapy--mixed results from mixed cells. *N Engl J Med.*, 2006, 355:1274-7.
- [9]. Reinecke H, Poppa V, Murry CE. Skeletal muscle stem cells do not transdifferentiate into cardiomyocytes after cardiac grafting. *J Mol Cell Cardiol.*, 2002, 34:241-9.
- [10]. Behfar A, Zingman L, Hodgson D, Rauzier J, Kane G, Terzic A, Puc  at M. Stem cell differentiation requires a paracrine pathway in the heart. *FASEB J.*, 2002, 16:1558-1566.
- [11]. M  nard C, Hag  ge A, Agbulut O, Barro M, Morichetti C, Brasselet C, Bel A, Messas E, Bissery A, Bruneval P, Desnos M, Puc  at M, Menasch   P. Xenograft of cardiac-committed embryonic stem cells to infarcted sheep myocardium improves left ventricular function: A preclinical study. *The Lancet*, 2005, 17-23; 366(9490):1005-12.
- [12]. Singla DK, Hacker TA, Ma L, Douglas PS, Sullivan R, Lyons GE, Kamp TJ. Transplantation of embryonic stem cells into the infarcted mouse heart: formation of multiple cell types. *J Mol Cell Cardiol.*, 2006, 40:195-200. Epub 2005 Nov 8.
- [13]. Laflamme MA, Gold J, Xu C, Hassanipour M, Rosler E, Police S, Muskheli V, Murry CE. Formation of human myocardium in the rat heart from human embryonic stem cells. *Am J Pathol.*, 2005, 167:663-71.
- [14]. Kolossov E, Bostani T, Roell W, Breitbart M, Pillekamp F, Nygren JM, Sasse P, Rubenchik O, Fries JW, Wenzel D, Geisen C, Xia Y, Lu Z, Duan Y, Kettenhofen R, Jovinge S, Bloch W, Bohlen H, Welz A, Hescheler J, Jacobsen SE, Fleischmann BK. Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium. *J Exp Med.*, 2006, 203:2315-27.
- [15]. Pera MF, Trounson AO. Human embryonic stem cells: prospects for development. *Development*, 2004, 131:5515-25.
- [16]. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res.*, 2001, 29:e45.
- [17]. Pal, R., and Khanna, A. (2007) Differentiation. 75, 112-122.
- [18]. Frasch M. Intersecting signalling and transcriptional pathways in *Drosophila* heart specification. *Semin Cell Dev Biol.*, 1999, 10:61-71.
- [19]. Reiter JF, Verkade H, Stainier DY. Bmp2b and Oep promote early myocardial differentiation through their regulation of gata5. *Dev Biol.*, 2001, 234:330-8.

- [20]. Breckenridge RA, Mohun TJ, Amaya E. A role for BMP signalling in heart looping morphogenesis in *Xenopus*. *Dev Biol.*, 2001, 232:191-203.
- [21]. Shi Y, Katsev S, Cai C, Evans S. BMP signaling is required for heart formation in vertebrates. *Dev Biol.*, 2000, 224:226-37.
- 5 [22]. Andree B, Duprez D, Vorbusch B, Arnold HH, Brand T. BMP-2 induces ectopic expression of cardiac lineage markers and interferes with somite formation in chicken embryos. *Mech Dev.*, 1998, 70:119-31.
- [23]. Massague J. Integration of Smad and MAPK pathways: a link and a linker revisited. *Genes Dev.*, 2003, 17:2993-7.
- 10 [24]. Greber B, Lehrach H, Adjaye J. FGF2 Modulates TGF{beta} Signaling in MEFs and Human ES cells to Support hESC Self-renewal. *Stem Cells*, 2006, 12:12.
- [25]. Behfar A, Perez-Terzic C, Faustino RS, Arrell DK, Hodgson DM, Yamada S, Puceat M, Niederlander N, Alekseev AE, Zingman LV, Terzic A. Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. *J Exp Med.*, 2007, 15 5:5.
- [26]. Laflamme MA, Murry CE. Regenerating the heart. *Nat Biotechnol.*, 2005, 23:845-56.
- [27]. Teng CJ, Luo J, Chiu RC, Shum-Tim D. Massive mechanical loss of microspheres with direct intramyocardial injection in the beating heart: implications for cellular cardiomyoplasty. *J Thorac Cardiovasc Surg.*, 2006, 132:628-32.
- 20 [28]. Damajanov I, Solter D, Skreb N. Teratocarcinogenesis as related to the age of embryos grafted under the kidney capsule. *Roux arch. Dev. Biol.*, 1971, 173:228-234.
- [29]. Kofidis T, Lebl DR, Swijnenburg RJ, Greeve JM, Klima U, Robbins RC. Allopurinol/uricase and ibuprofen enhance engraftment of cardiomyocyte-enriched human embryonic stem cells and improve cardiac function following myocardial injury. 25 *Eur J Cardiothorac Surg*, 2006, 29:50-5. Epub 2005 Dec 6.
- [30]. Teichmann U, Kessel M. Highly restricted BMP10 expression in the trabeculating myocardium of the chick embryo. *Dev Genes Evol.*, 2004, 214:96-8.
- [31]. Menard C, Hagege AA, Agbulut O, Barro M, Morichetti MC, Brasselet C, Bel 30 A, Messas E, Bissery A, Bruneval P, Desnos M, Puceat M, Menasche P. Transplantation of cardiac-committed mouse embryonic stem cells to infarcted sheep myocardium: a preclinical study. *Lancet*, 2005, 366:1005-12.

- [32]. Kehat, I., Khimovich, L., Caspi, O., Gepstein, A., Shofti, R., Arbel, G., Huber, I., Satin, J., Itskovitz-Eldor, J., and Gepstein, L. (2004) *Nat Biotechnol*, 22, 1282-1289.
- [33]. Leobon B, Garcin I, Menasche P, Vilquin JT, Audinat E, Charpak S. Myoblasts transplanted into rat infarcted myocardium are functionally isolated from their host. *Proc Natl Acad Sci U S A*, 2003, 12:12.
- [34]. Lagostena L, Avitabile D, De Falco E, Orlandi A, Grassi F, Iachininoto MG, Ragone G, Fucile S, Pompilio G, Eusebi F, Pesce M, Capogrossi MC. Electrophysiological properties of mouse bone marrow c-kit⁺ cells co-cultured onto neonatal cardiac myocytes. *Cardiovasc Res.*, 2005, 66:482-92.
- [35]. Smith, A.G. Embryo-derived stem cells: of mice and men. *Annu Rev Cell Dev Biol* 17, 435-462 (2001).
- [36]. Cezar, G.G. Can human embryonic stem cells contribute to the discovery of safer and more effective drugs? *Curr Opin Chem Biol.* 11, 405-409 (2007).
- [37]. Bushway, P.J. & Mercola, M. High-throughput screening for modulators of stem cell differentiation. *Methods Enzymol.* 414, 300-316 (2006).
- [38]. Puceat, M. & Ballis, A. Embryonic stem cells: from bench to bedside. *Clin Pharmacol Ther.* 82, 337-339 (2007).
- [39]. Cowan, C.A. et al. Derivation of embryonic stem-cell lines from human blastocysts. *N Engl J Med.* 350, 1353-1356 (2004).
- [40]. Amit, M. & Itskovitz-Eldor, J. Derivation and maintenance of human embryonic stem cells. *Methods Mol Biol.* 331, 43-53 (2006).
- [41]. Mitalipov, S. et al. Isolation and characterization of novel rhesus monkey embryonic stem cell lines. *Stem Cells.* 24, 2177-2186 (2006).
- [42]. Tomescot, A. et al. Differentiation in vivo of cardiac committed Human embryonic stem cells in post-myocardial infarcted rats. *Stem Cells.* 25, 2200-2205 (2007).
- [43]. Zeineddine, D. et al. Oct-3/4 dose dependently regulates specification of embryonic stem cells toward a cardiac lineage and early heart development. *Dev Cell.* 11, 535-546 (2006).
- [44]. Stefanovic, S. & Puceat, M. Oct-3/4: not just a gatekeeper of pluripotency for embryonic stem cell, a cell fate instructor through a gene dosage effect. *Cell Cycle.* 6, 8-10 (2007).

- [45]. Yao, S. et al. Long-term self-renewal and directed differentiation of human embryonic stem cells in chemically defined conditions. *Proc Natl Acad Sci U S A*. **103**, 6907-6912 (2006).
- [46]. Takahashi K, et al., Induction of Pluripotent Stem Cells from Adult Human
5 Fibroblasts by Defined Factors; *Cell*. 2007 Nov 30; 131(5):861-72.
- [47]. Nakagawa et al., Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts; *Nat Biotechnol*. 2008; 26(1):101-6).
- [48]. Wernig et al., In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. *Nature*, 2007, 448(7151):318-24.
- 10 [49]. Maherali N et al. High-efficiency system for the generation and study of human induced pluripotent stem Cell *Stem Cell* 3 345-350 (2008).

CLAIMS:

1. A method for the *in vitro* preparation of cardiovascular progenitor cells from primate ES cells, wherein said method comprises the following steps of:

a) culturing primate ES cells in a medium containing suitable agents allowing their proliferation and maintaining their pluripotency;

b) differentiating the primate pluripotent ES cells obtained in step a) toward cardiovascular progenitor cells by suspending said pluripotent ES cells in a medium containing BMP2 (Bone Morphogenetic Protein 2); and

c) selecting and collecting the differentiated primate ES cells obtained in step b) which display the CD15 marker at their membrane surface, the primate cells displaying said CD15 marker being selected and collected as cardiovascular progenitor cells.

2. The method according to claim 1, wherein the medium of step a) comprises a platelet lysate.

3. The method according to claim 2, wherein said platelet lysate is a lysate of platelet-rich plasma (PRP).

4. The method according to any one of claims 1 to 3, wherein the medium of step a) comprises a platelet lysate to wholly or partly replace foetal animal serum usually present in the medium used for culturing primate ES cells.

5. The method according to claim 4, wherein said primate cells are human cells.

6. The method according to any one of claims 1 to 5, wherein in step b) said BMP2 is a human BMP2.

7. The method according to any one of claims 1 to 6, wherein in step b) the medium further contains a receptor tyrosine kinase (RTK) inhibitor.

8. The method according to claim 7, wherein said RTK inhibitor is selected from the group consisting of: a FGFR (fibroblast growth factor receptor) and a multitargeted tyrosine kinase receptor inhibitor.

9. The method according to claim 8, wherein said multitargeted tyrosine kinase receptor inhibitor results in the inhibition of the tyrosine kinase activity of at least one of the following receptors: the VEGFR (vascular endothelial growth factor receptor), VEGFR-1, VEGFR-2, fetal liver tyrosine kinase receptor 3 (FLT3), KIT (stem-cell factor [SCF] receptor), PDGFR α , and PDGFR β .

10. The method according to claim 8 or 9, wherein said RTK inhibitor is selected from the group consisting of: SU5402 (3-[3-(2-Carboxyethyl)-4-methylpyrrol-2-methylidenyl]-2-indolinone, SU11248 (N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide) and salts thereof.

11. The method according to any one of claims 1 to 10, wherein in step b), the ES cells are treated with 10 ng/ml $\pm$ 5 ng/ml BMP2 in the presence of 1 μ M $\pm$ 0.5 μ M SU5402.

12. The method according to claim 11, wherein in step b), the ES cells are treated with 10 $\pm$ 5 ng/ml BMP2 in the presence of 1 $\pm$ 0.5 μ M SU5402, for respectively 48 hrs and 6 days.

13. The method according to any one of claims 1 to 10, wherein in step b), the ES cells are treated with 10 $\pm$ 5 ng/ml BMP2 in the presence of 5 $\pm$ 2 μ M SU11248.

14. The method according to claim 13, wherein in step b), the ES cells are treated with 10 $\pm$ 5 ng/ml BMP2 in the presence of 5 $\pm$ 2 μ M SU11248, respectively for 48 hrs and 6 days.

15. The method according to any one of claims 1 to 10, wherein in step b), the ES cells are treated for 96 hours with 10 ng/ml BMP2 in RPMI supplemented with 2 % B27 and:

- 1 μ M SU5402; or
- 5 μ M SU11248.

16. The method according to claim 15, wherein said SU5402 is of research grade, and wherein said SU11248 is of clinical grade.

17. The method according to any one of claims 1 to 16, wherein in step a) the medium containing suitable agents allowing the proliferation of primate ES cells and maintaining their pluripotency comprises a basic medium supplemented with platelet lysate obtained from primate blood.

18. The method according to claim 17, wherein said platelet lysate is added to the basic medium at a concentration of $7.5 \% (V/V) \pm 2.5 \%$.

19. A substantially purified population of cardiovascular progenitor cells obtained by the method according to any one of claims 1 to 18, wherein the cardiovascular progenitor cells display at their membrane surface the CD15 marker.

20. The substantially purified population of cardiovascular progenitor cells according to claim 19, wherein the cardiovascular progenitor cells retain their capability to proliferate and repopulate a postinfarction scar of a patient in need thereof.

21. The substantially purified population of cardiovascular progenitor cells according to claim 20, wherein said cardiovascular progenitor cells further display the early mesodermal Brachyury and Tbx6 markers, the cardiac Tbx20 and Mef2c markers, the Nkx2.5 marker and the Oct-4A marker.

22. Use of a substantially purified population of cardiovascular progenitor cells according to any one of claims 19 to 21, for the preparation of a medicament for treating heart failure.

23. The use of a substantially purified population of cardiovascular progenitor cells according to claim 22, for treating heart failure in a primate.

24. The use of a substantially purified population of cardiovascular progenitor cells according to claim 23, for treating heart failure in a human.

25. A method for selectively separating cardiovascular progenitor cells from a primate cell population containing non-differentiated ES cells and cardiovascular progenitor cells, or a method for enriching in cardiovascular progenitor cells a primate cell population comprising cells

displaying a CD15 marker at their membrane surface, wherein said method comprises the following steps of:

A) contacting the primate cell population with anti-CD15 antibodies; and

B) selecting and collecting the cells that bind specifically to the CD15 antibodies or eliminating the cells which are not bound to the anti-CD15 antibodies.

26. The method according to claim 25, wherein said anti-CD15 antibodies are anti-human antibodies.

27. The method according to claim 25 or 26, wherein said anti-CD15 antibodies are bound to the surface of magnetic beads or particles or coupled to magnetic compounds.

28. The method according to any one of claims 25 to 27, wherein the anti-CD15 antibodies are labelled.

29. The method according to claim 28, wherein the anti-CD15 antibodies are labelled with a fluorescent or a magnetic marker.

30. The method according to claim 29 wherein the fluorescence-activated cells sorting (FACS) technique is used.

31. A kit for enriching for cardiovascular progenitor cells from a cell population containing non-differentiated primate ES cells and cardiovascular progenitor cells, or from a cell population containing non-differentiated embryonic-like state cells and cardiovascular progenitor cells, wherein the kit comprises anti-CD15 antibodies and reagents used for performing a gene expression profile of at least one cardiovascular gene chosen among Nkx2.5, Gata4, and Isl1.

32. The kit according to claim 31, wherein said kit comprises anti-human CD15 antibodies.

33. The kit according to claim 32, wherein said antibodies are labelled.

1/18

% beating EBs




FIGURE 1




FIGURE 2

2/18





FIGURE 3A

3/18




FIGURE 3B




FIGURE 3C

4/18




FIGURE 3D

5/18




FIGURE 4A

6/18




FIGURE 4B

7/18




FIGURE 5

8/18




FIGURE 6A




FIGURE 6B

9/18




FIGURE 7




FIGURE 8A

10/18




FIGURE 8B




FIGURE 8C

11/18




FIGURE 8D




FIGURE 9

12/18




FIGURE 10A

13/18





FIGURE 10B

14/18




FIGURE 11A




FIGURE 11B

16/18




FIGURE 11B(continuing)

17/18




FIGURE 11B(continuing)

18/18





FIGURE 11C

